CCWM
PPH icon

Cassaday & Co Wealth Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Cassaday & Co Wealth Management’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-760
Closed -$78.9K – 1408
2026
Q1 		$78.9K Buy
+760
New +$81K ﹤0.01% 511

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return
AWC
Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Cassaday & Co Wealth Management's PPH Position: Q2 2026 in Review

Cassaday & Co Wealth Management sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2026, closing a stake of 760 shares — an estimated $78.9K sold.

Cassaday & Co Wealth Management first reported a position in PPH in Q1 2026 and held it in 1 quarter. The position peaked at $78.9K in Q1 2026. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

  • Cassaday & Co Wealth Management reported no remaining VanEck Pharmaceutical ETF position as of Q2 2026 after selling out during the quarter.
  • Cassaday & Co Wealth Management sold 760 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $78.9K.
  • Cassaday & Co Wealth Management first reported a position in VanEck Pharmaceutical ETF in Q1 2026 and held it in 1 quarter.
  • Cassaday & Co Wealth Management's VanEck Pharmaceutical ETF position peaked at $78.9K in Q1 2026.
  • 148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.